A last-minute provision, passed with budget legislation, may give Massachusetts a state-run bulk pharmaceutical purchasing program.
A last-minute provision, passed with budget legislation, may give Massachusetts a state-run bulk pharmaceutical purchasing program. If implemented, the state-sponsored program would be run by a third party and would negotiate discounts with pharmaceutical companies for underinsured members of the state's 1.5 million citizens.
Pharmaceutical companies have reacted harshly to the program, which they say is vague and ill-conceived. "[The Massachusetts state government is] going to set up a government-controlled, bulk-purchasing program for the Commonwealth of Massachusetts for 'all the underinsured folks in the state.' Well, what does that mean?" asked Jeff Trewhitt, spokesman for the Washington-based Pharmaceutical Research and Manufacturers of America. "Are they talking about half the state, a fourth [of] the state, or what? There is no precise definition there."
According to PhRMA, the state's Medicaid and senior pharmacy programs are already in place to serve the senior population. By taking seniors out of those established programs and enrolling them in the new program, Massachusetts would sacrifice $73 million worth of rebates through Medicaid and $2 million in rebates through the senior pharmacy program.
Despite the fact that it would be run by a third party - most likely former Rep. Joseph Kennedy's not-for-profit company, Citizens Energy Corp. - the government-controlled aspect of the program is what has PhRMA worried the most. "If you look at bulk purchasing programs in other industries, you see a tendency to put price controls into place," said Trewhitt. "There is that strong potential here because this is going to be a state-run program. And [whenever] any government entity gets into a program where, all of a sudden, the cost is greater than expected, the inclination is to slap on price controls or engage in rationing. Neither option is very attractive." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.